# A Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer

Source: https://onco.cc/trials/nct03431350/  
OnCo record `nct03431350` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Niraparib, Cetrelimab, Abiraterone acetate and Prednisone in prostate cancer, run by Janssen Research & Development, LLC, active and no longer recruiting.

## Summary

A Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer is a phase 2 interventional study registered as NCT03431350 by Janssen Research & Development, LLC, with 136 participants enrolled, started 2018-03-02 and due to reach its primary completion in 2021-08-31. Interventions recorded: Niraparib 200 mg, Cetrelimab 240 mg, Cetrelimab 480 mg, Abiraterone acetate 1000 mg and Prednisone 5 mg. Results have been posted on the registry.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT03431350
- Phase: 2
- Setting: A Phase 1b-2 Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer
- Sponsor: Janssen Research & Development, LLC
- Enrolled: 136

## Sources

- ClinicalTrials.gov NCT03431350: https://clinicaltrials.gov/study/NCT03431350

## Connected records

- cancers: [Prostate cancer](https://onco.cc/cancers/prostate/)
- drugs: [Abiraterone acetate](https://onco.cc/drugs/abiraterone/), [Cetrelimab](https://onco.cc/drugs/cetrelimab/), [Niraparib](https://onco.cc/drugs/niraparib/), [Prednisone](https://onco.cc/drugs/prednisone/)
- companies: [Johnson & Johnson](https://onco.cc/companies/johnson-johnson/)

---
JSON: https://onco.cc/api/v1/entities/nct03431350.json